News that daclizumab, brand name Zinbryta, has been given the go-ahead to be available through the U.K.’s National Health Service (NHS) for treating relapsing MS, at least in part of the country, is good news. But why has the decision taken so long? Possibly, because the first decision, last September, was ‘no.’ The latest decision by … Continue reading After Long Wait, Zinbryta Gains Approval in Areas of the UK
approval
New MS drug approval delayed by three months
People with MS who have been looking forward to the long-awaited US Food and Drug Administration (FDA) approval of the MS drug Ocrevus (ocrelizumab) are disappointed now it has been delayed. This is because, although a decision had been promised for late December 2016, an 11th-hour decision means the approval hearing has now been put … Continue reading New MS drug approval delayed by three months
